title: Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours.
abstract: We studied the effect of a tilorone analogue (RMI 10,874DA) and anti-asialo GM(1) serum on the survival of BALB/c and C57B1/6 mice after i.v. injections of different syngeneic murine tumour cells. Tumour lines used were different clones from chemically (GR9 wild type, GR9.B9, B7.1.B4, B7.1.B5, B7.2.38), and ultraviolet light (GRUV3)-induced sarcomas; B16 melanoma and LSTRA and YC8 lymphomas. Pretreatment of mice with tilorone inhibited metastatic colonization and increased survival significantly in all cases. In some tumour systems, the effect was attenuated when high numbers of cells were injected. Abrogation of NK cells with anti-asialo GM(1) serum significantly decreased (in all tumours and at different cell doses) survival in comparison with untreated mice injected with tumours, regardless of cell dose used. These results clearly suggest that NK cell activation in vivo by the tilorone analogue we tested prolongs survival and inhibits metastasis formation in mice, even when pretreatment consists of a single dose of the analogue.
authors.affiliation: Department of Clinical Analysis and Immunology, Hospital Virgen de las Nieves, Universidad de Granada, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Algarra
authors.forename: A
authors.initials: A
authors.lastname: González
authors.forename: M
authors.initials: M
authors.lastname: Pérez
authors.forename: J J
authors.initials: JJ
authors.lastname: Gaforio
authors.forename: F
authors.initials: F
authors.lastname: Garrido
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005677:G(M1) Ganglioside / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D008207:Lymphatic Metastasis; D008213:Lymphocyte Activation / Q000187:drug effects*; D008223:Lymphoma / Q000188:drug therapy; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000556:secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000556:secondary*; D012680:Sensitivity and Specificity; D013154:Spleen / Q000166:cytology; D013994:Tilorone / Q000494:pharmacology; D014966:Xanthenes / Q000494:pharmacology*; D044004:Xanthones
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D015395:Histocompatibility Antigens Class I; D014966:Xanthenes; D044004:Xanthones; D005677:G(M1) Ganglioside; C081584:RMI 10874DA; C018835:asialo GM1 ganglioside; D013994:Tilorone